Sponsor pipeline

Neonc Technologies, Inc. clinical trial pipeline

Get alerts when Neonc Technologies, Inc.'s trials change

4 active trials 3 recruiting 13 disease areas 5 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-16

What changed in the last 30 days

2026-09-15
Primary completion pushed: 2026-07-30 → 2026-11-30
Completion pushed: 2026-08 → 2026-12
NCT02704858 Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma · Phase 1/2
2026-09-16
Primary completion pushed: 2026-10 → 2027-06
Recruitment opened
Completion pushed: 2026-10 → 2027-07
NCT06357377 A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain… · Phase 1

Active trials by phase

Phase 1
1
Phase 1/2
2
Phase 2
1

Active trials

NCT IDTitleConditionStatusUpdated
Phase 2
NCT05023018 NEO100 and High-Grade Meningioma Residual, Progressive or Recurrent Grade II or III Meningioma Recruiting 2026-09-15
Phase 1/2
NCT06047379 Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma… Diffuse Astrocytoma, IDH-Mutant Recruiting 2026-09-15
NCT02704858 Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma Glioblastoma Multiforme Active, Not Recruiting 2026-09-14
Phase 1
NCT06357377 A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain… Pediatric Tumor of CNS Recruiting 2026-09-15

Disease areas by active trials, top 10 of 13

Glioblastoma (2) · Glioma (2) · Bladder Cancer (1) · Cervical Cancer (1) · Colorectal Cancer (1) · Esophageal Cancer (1) · Gastric Cancer (1) · Head & Neck Cancer (1) · Kidney Cancer (1) · Lung Cancer (1)

Get alerts when Neonc Technologies, Inc.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free